IBMX
Names
IUPAC name
1-Methyl-3-(2-methylpropyl)-7H -purine-2,6-dione
Other names
3-Isobutyl-1-methylxanthine
Identifiers
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard
100.044.767
KEGG
UNII
InChI=1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)
Y Key: APIXJSLKIYYUKG-UHFFFAOYSA-N
Y InChI=1/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)
Key: APIXJSLKIYYUKG-UHFFFAOYAL
CC(C)Cn1c2c(c(=O)n(c1=O)C)[nH]cn2
Properties
C10 H14 N4 O2
Molar mass
222.3 g/mol
Appearance
White solid
Melting point
199 to 201 °C (390 to 394 °F; 472 to 474 K)
Solubility
Soluble in ethanol, DMSO, and methanol
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
Chemical compound
IBMX (3-isobutyl-1-methylxanthine), like other methylxanthine derivatives , is both a:
competitive non-selective phosphodiesterase inhibitor [ 1] which raises intracellular cAMP , activates PKA , inhibits TNFα [ 2] [ 3] and leukotriene [ 4] synthesis, and reduces inflammation and innate immunity ,[ 4] and
nonselective adenosine receptor antagonist.[ 5]
As a phosphodiesterase inhibitor , IBMX has IC50 = 2–50 μ M[ 6] and does not inhibit PDE8 or PDE9 .[ 7]
^ Essayan, DM (November 2001). "Cyclic Nucleotide Phosphodiesterases" . The Journal of Allergy and Clinical Immunology . 108 (5): 671– 80. doi :10.1067/mai.2001.119555 . PMID 11692087 .
^ Deree, J; Martins, JO; Melbostad, H; Loomis, WH; Coimbra, R (June 2008). "Insights into the Regulation of TNF-α Production in Human Mononuclear Cells: The Effects of Non-Specific Phosphodiesterase Inhibition" . Clinics (Sao Paulo) . 63 (3): 321– 8. doi :10.1590/S1807-59322008000300006 . PMC 2664230 . PMID 18568240 .
^ Marques, LJ; Zheng, L; Poulakis, N; Guzman, J; Costabel, U (February 1999). "Pentoxifylline Inhibits TNF-α Production from Human Alveolar Macrophages" . American Journal of Respiratory and Critical Care Medicine . 159 (2): 508– 11. doi :10.1164/ajrccm.159.2.9804085 . PMID 9927365 .
^ a b Peters-Golden, M; Canetti, C; Mancuso, P; Coffey, MJ (15 January 2005). "Leukotrienes: Underappreciated Mediators of Innate Immune Responses" (PDF) . Journal of Immunology . 174 (2): 589– 94. doi :10.4049/jimmunol.174.2.589 . PMID 15634873 .
^ Daly, JW; Jacobson, KA; Ukena, D (1987). "Adenosine Receptors: Development of Selective Agonists and Antagonists". Progress in Clinical and Biological Research . 230 : 41– 63. PMID 3588607 .
^ Beavo, JA; Rogers, NL; Crofford, OB; Hardman, JG; Sutherland, EW; Newman, EV (November 1970). "Effects of Xanthine Derivatives on Lipolysis and on Adenosine 3',5'-Monophosphate Phosphodiesterase Activity". Molecular Pharmacology . 6 (6): 597– 603. PMID 4322367 .
^ Soderling, SH; Beavo, JA (April 2000). "Regulation of cAMP and cGMP Signaling: New Phosphodiesterases and New Functions". Current Opinion in Cell Biology . 12 (2): 174– 9. doi :10.1016/s0955-0674(99)00073-3 . PMID 10712916 .